Capital International Inc. CA Has $55.65 Million Holdings in AbbVie Inc. $ABBV

Capital International Inc. CA lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 39.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 240,358 shares of the company’s stock after purchasing an additional 67,912 shares during the quarter. Capital International Inc. CA’s holdings in AbbVie were worth $55,652,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Norges Bank acquired a new position in shares of AbbVie during the second quarter valued at about $4,288,200,000. Laurel Wealth Advisors LLC boosted its stake in AbbVie by 18,384.4% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after purchasing an additional 3,380,842 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in shares of AbbVie by 169.3% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock valued at $876,662,000 after purchasing an additional 2,969,202 shares in the last quarter. Finally, Raymond James Financial Inc. grew its holdings in AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after buying an additional 2,753,312 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ABBV. Evercore dropped their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Royal Bank Of Canada began coverage on shares of AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price for the company. Barclays initiated coverage on shares of AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target on the stock. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research report on Tuesday, January 20th. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $253.15.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase 1 ABBV‑295 (long‑acting amylin analog) topline results showed clinically meaningful weight loss (~7.8%–9.8% at ~12–13 weeks) with a favorable tolerability profile, supporting continued development of a non‑incretin obesity treatment — a potential new growth driver outside AbbVie’s GI/immunology franchise. AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
• Positive Sentiment: Positive topline Phase 3 AFFIRM results for SKYRIZI (risankizumab) in Crohn’s disease increase the likelihood of label expansion and incremental revenue from AbbVie’s immunology franchise. This helps the company’s growth outlook beyond its legacy products. AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease
• Positive Sentiment: Major broker support remains — J.P. Morgan has stuck with a buy rating, which can help stabilize sentiment amid pipeline news and support investor demand. J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
• Neutral Sentiment: Analyst and retail attention is rising (momentum screens and coverage), which can amplify moves but doesn’t guarantee directional conviction; investors should watch follow‑on data and commercialization signals. Here’s Why AbbVie (ABBV) is a Strong Momentum Stock
• Neutral Sentiment: Recent trial updates (Crohn’s + ABBV‑295) are being used to re‑price AbbVie’s mid‑term valuation; they add context but require regulatory, commercial and longer‑term outcome confirmation. AbbVie Trial Updates Add Context To Valuation And Growth Outlook
• Negative Sentiment: ICER will review AbbVie’s Parkinson’s disease drug, introducing potential pricing and reimbursement scrutiny that could limit commercial upside or pressure expected margins for that program. ICER to review AbbVie’s Parkinson’s disease drug
• Negative Sentiment: Market reaction has been mixed — reports note shares fell after the early obesity data, suggesting investors may be taking profits or weighing valuation against what remains early‑stage evidence. AbbVie’s Early Obesity Drug Data Shows Up To 10% Weight Loss
• Negative Sentiment: An AbbVie SVP sold about $1.22M of stock; insider sales can be read as a near‑term negative signal even if not uncommon at large companies. AbbVie (NYSE:ABBV) SVP Sells $1,221,518.80 in Stock

AbbVie Price Performance

Shares of NYSE:ABBV opened at $227.75 on Tuesday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company has a market capitalization of $402.70 billion, a PE ratio of 96.50, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The business has a fifty day moving average price of $224.66 and a two-hundred day moving average price of $224.33.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is presently 293.22%.

Insider Buying and Selling

In related news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is owned by corporate insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.